Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Lensar (LNSR) Receivables - Other (2022 - 2025)

Lensar (LNSR) reported Receivables - Other of $38000.0 for Q2 2025, down 93.93% year-over-year from $626000.0 in Q2 2024, and down 73.61% on a QoQ basis from $144000.0 in Q1 2025.

Lensar (LNSR) has 4 years of Receivables - Other data on file, last reported at $38000.0 in Q2 2025.

  • Quarterly Receivables - Other fell 93.93% year-over-year to $38000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $38000.0 (down 93.93% YoY) and the FY2024 annual result came in at $236000.0, down 75.97% from the prior year.
  • Receivables - Other eased to $38000.0 in Q2 2025 per LNSR's latest filing, from $144000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $982000.0 in Q4 2023 and bottomed at $38000.0 in Q2 2025.
  • The 4-year median for Receivables - Other is $498500.0 (2023), against an average of $493333.3.
  • The widest annual swing landed in 2023, when Receivables - Other surged 1225.37%; it then tumbled 93.93% in 2025.
  • Tracing LNSR's Receivables - Other over 4 years: stood at $332000.0 in 2022, then jumped by 195.78% to $982000.0 in 2023, then plunged by 75.97% to $236000.0 in 2024, then sank by 83.9% to $38000.0 in 2025.
  • Per Business Quant, the three latest LNSR Receivables - Other figures stand at $38000.0 (Q2 2025), $144000.0 (Q1 2025), and $236000.0 (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Lensar 69.32 Mn 69.61 Mn 6.38 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 38,000.00
Jun 30, 2025 38,000.00
Mar 31, 2025 144,000.00
Mar 31, 2025 144,000.00
Dec 31, 2024 236,000.00
Dec 31, 2024 236,000.00
Sep 30, 2024 593,000.00
Sep 30, 2024 593,000.00
Jun 30, 2024 626,000.00
Jun 30, 2024 626,000.00
Mar 31, 2024 785,000.00
Mar 31, 2024 785,000.00
Dec 31, 2023 982,000.00
Dec 31, 2023 982,000.00
Sep 30, 2023 888,000.00
Sep 30, 2023 888,000.00
Jun 30, 2023 825,000.00
Jun 30, 2023 825,000.00
Mar 31, 2023 404,000.00
Mar 31, 2023 404,000.00
Dec 31, 2022 332,000.00
Dec 31, 2022 332,000.00
Sep 30, 2022 67,000.00
Sep 30, 2022 67,000.00